Mitsubishi Tanabe Deal History & Licensing Activity
Mitsubishi Tanabe is a large pharma headquartered in Japan. Over the past three years, Mitsubishi Tanabe has been involved in 2 licensing and acquisition transactions, with a primary focus on mRNA (2 deals).
Deals (12mo)
1
Active Trials
25
Top Modality
mRNA
Focus Area
Infectious Disease
Mitsubishi Tanabe Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Mitsubishi Tanabe in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| mRNA respiratory vaccine portfolio | Mitsubishi Tanabe Pharma | mRNA | Approved | collaboration | Jul 2025 |
| Uplizna | Bain Capital | Antibodies | Approved | acquisition | Jul 2025 |
Mitsubishi Tanabe Pipeline Focus
Therapeutic areas and modalities where Mitsubishi Tanabe is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Mitsubishi Tanabe Strategic Signals
Key indicators of Mitsubishi Tanabe's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
See How Your Asset Matches Mitsubishi Tanabe's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Infectious Disease assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Infectious Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for infectious disease
Neurology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for neurology
mRNA Benchmarks
Upfront, milestone, and royalty benchmarks for mrna deals
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
About Mitsubishi Tanabe Licensing & Deal Activity
Mitsubishi Tanabe is a large pharma company based in Japan that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Mitsubishi Tanabe ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Mitsubishi Tanabe include Infectious Disease (2 deals and trials), and Neurology (2 deals and trials). In terms of modality, Mitsubishi Tanabe has shown particular interest in mrna, antibodies.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Mitsubishi Tanabe and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Mitsubishi Tanabe's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.